Apr 18, 2022 | About CMT, Life with CMT
Published by CMT News (slightly edited for clarity) It was an unexpected $1 million gift, even for Kent and Michele Stahl. The Charcot-Marie-Tooth Research Foundation (CMTRF) was hosting a research convention in September when it announced Endgame, the...
Apr 11, 2022 | About CMT, CMT Research Updates
Nearly every instance of CMT is caused by the mutation of a single gene and most genetic causes of CMT have been identified. The era of genetic medicine has already begun. The FDA first approved genetic medicines in 2016/2017. This set the foundation for a precision...
Mar 22, 2022 | About CMT, News, Research news
By Keith Fargo, Chief Scientific Officer At the CMT Research Foundation, we believe that more is achieved when people work together than when they work individually. This is especially true in biomedical research. Over the past few decades, a seismic shift has...
Jun 27, 2021 | About CMT, CMT Research Updates, CMTRF Funded Research, Drug Development, Small Molecule Therapies, Therapy Types
The CMT Research Foundation is proud to announce our latest project, a partnership between AcuraStem, a patient-based drug discovery platform company, and Dr. Alessandra Bolino, a renowned expert in CMT and the head of the Human Inherited Neuropathies Unit at the...
Jan 11, 2021 | About CMT, CMT Research Updates, Drug Development, News, Research news
By: Susan Ruediger, CEO, CMT Research Foundation It costs more than $2.6 billion to develop an approved prescription medicine (Journal of Health Economics, 2016) and typically takes between 10 to 15 years to get a drug to clinical trials (Neuron, 2014). With no...